DDOG is good stuff! $200 next year? Your SOUN has a 52 week high of $10.25, when are we taking it out?
HOOD is unstoppable, I thought someone would have bought them out when they were $10-$18. “ Notable profits for the buyer who lifted the $0.80 offer for 2,071 Robinhood () 11/29 weekly 36 calls yesterday at 09:43ET when underlying shares were trading at $34.89. Shares closed at $36.65, and the calls at $1.51 for a mark-to-market profit of 89%, or $147K, on the $166K outlay.” TipRanks “ Morgan Stanley Upgrades Robinhood(HOOD.US) to Buy Rating, Raises Target Price to $55 $Robinhood (HOOD.US)$ to a buy rating, and adjusts the target price from $21 to $55. According to TipRanks data, the analyst has a success rate of 55.1% and a total average return of 6.4% over”
“ Palantir Surges In Monday Pre-Market As Top Tech Bull Raises Price Target To $75 Ahead Of Nasdaq Listing Benzinga· 27 mins ago ·Ratings 2mins Palantir (PLTR.US) 64.35067.050 +4.87% +4.20% The Campbell's Co (CPB.US) 45.29045.300 +1.87% +0.02% Science Applications International (SAIC.US) 124.200125.490 -0.46% +1.04% Palantir Technologies Inc. (NYSELTR) experienced a 3.25% increase in pre-market trading on Monday, as per Benzinga Pro. This rise follows the company's recent announcement of its transition from the NYSE to the Nasdaq, with trading set to begin on Nov. 26. Palantir's stock will continue under the ticker "PLTR." The move to Nasdaq is part of a broader trend, as the exchange has attracted 16 significant companies this year, including Science Applications International Corp (NYSE:SAIC) and Campbell Soup Company (NYSE:CPB). While Palantir has not confirmed any plans to join the Nasdaq-100, the potential inclusion could enhance its visibility and attract investor interest. Historically, companies switching to Nasdaq have often joined this prestigious index, which could lead to increased demand for Palantir shares.” Benzinga
SAVA -84% to $4 “ Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results Benzinga· 04:31 6mins Cassava Sciences (SAVA.US) 26.4804.410 -17.71% -83.35% Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company"))), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. Simufilam continued to demonstrate an overall
Hopefully sooner than later. I'm frantically cleaning this house I want to get out by 12 and home by 2. Tenaya Therapeutics doses first patient with TN-401 gene therapy » 08:37 TNY
I don't have a gambling problem. Yes I just placed a bet on Abilene Christian but I have a good feeling. We have two heritage birds in transit and will have to cook one on wed. I finally tackled that microwave. I have been living in such fear. I replaced the high voltage outlet. It blew again then I did what van told me to do originally get an extension cord and try another wall outlet. Blew that one too-- it's the damn microwave. This is a BOSCH they are fancy. this fucking thing has been asked to do nothing but warm up coffee for ten years, I don't even cook with it- just coffee & tell the time and the occasional mashed potatoes 2 minutes That's it. and it broke. They tell me don't even try and get a guy to fix because it will cost so much compared to buying a new one but when this bad boy came out out was a$1,000 machine. I'm tempted to try and get someone here to fix it but it will never get done by Thanksgiving.
I heard Archer went nuts today./ We should get that reversal Van warned about tomm. Trump and his tariffs won't help...